@tpf3891
At present there is only one market where an MSC solution is licensed for use, Japan.
What are the current sales for Temcell in Japan, as distinct from royalty payments, post the expansion out of the initial testing sites by JCR? I think my question is about as valid as your assertion about sales.
Along the lines of stanjupiters recent excellent post, what would the income be in the US if it were used as a first line treatment in place of steroids, as opposed to only in steroid refractory patients?
Why do you class the read outs for treatments for CHF and CLBP as riskier compared to that for aGVHD?
Ann: MSB Enters Into $75 Million Non-Dilutive Credit Facility, page-189
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
0.015(1.60%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | 95.5¢ | 94.0¢ | $385.6K | 406.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2970 | 95.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.5¢ | 91352 | 15 |
View Market Depth
| Last trade - 11.33am 12/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |